Systematic review of clinical guidelines and consensus statements concerning heparin and protamine dosing and monitoring of anticoagulation levels for non-cardiac arterial procedures
Restricted accessReview articleFirst published online October, 2025
Systematic review of clinical guidelines and consensus statements concerning heparin and protamine dosing and monitoring of anticoagulation levels for non-cardiac arterial procedures
This systematic review was performed to examine all published practice Guidelines and Consensus Statements (together: GCS) on heparin dosing and monitoring during non-cardiac arterial procedures (NCAP). The objective was to scrutinize the recommendations and advice outlined within these GCS documents and to evaluate the supporting evidence for these recommendations. Additionally, the use of the activated clotting time (ACT) and target ACT values were explored.
Methods
This systematic review was performed in accordance with the PRISMA Guidelines. Medline and Embase databases were searched to identify all GCSs in the English language on NCAP. The final literature search was performed in January 2023. This search was supplemented by searching websites of relevant professional vascular surgical organizations for GCSs. Titles and abstracts were assessed by two independent reviewers.
Results
Of 9716 titles identified, 27 GCSs met the predefined inclusion criteria: six GCSs regarding carotid intervention, seven regarding procedures for aneurysmal disease of the abdominal aorta and iliac arteries, 12 regarding interventions for acute and chronic peripheral arterial occlusive disease and two regarding open and endovascular interventions of thoraco-abdominal aortic aneurysms. Administration of heparin is advised for al NCAP. There was high variability concerning heparin dose: both standard dose as weight based dosing (30-150 IU/kg) was advised. Recommendations on repeated doses, ACT monitoring and heparin reversal using protamine also varied widely. In none of the GCSs, the type of the ACT measuring device or used cartridges were specified.
Conclusions
Large variability was found between the included GCSs with regard to the recommendations on heparin dose and target ACT values during NCAP. Advice and recommendations in GCSs were based on low-quality studies or without providing any reference at all. The described variability in recommendations emphasizes the need for large prospective (randomized) studies or the incorporation of data on heparin and the use of ACT monitoring into verified vascular surgery registries, to develop evidence-based, practical and uniform applicable recommendations.
SmilowitzNRGuptaNRamakrishnaH, et al.Perioperative major adverse cardiovascular and cerebrovascular events associated with noncardiac surgery. JAMA Cardiol2017; 2: 181–187. DOI: 10.1001/JAMACARDIO.2016.4792.
2.
EgorovaNNGuillermeSGelijnsA, et al.An analysis of the outcomes of a decade of experience with lower extremity revascularization including limb salvage, lengths of stay, and safety. J Vasc Surg2010; 51: 878–885. DOI: 10.1016/J.JVS.2009.10.102.
3.
AlOthmanOBobatS. Comparison of the short and long-term outcomes of endovascular repair and open surgical repair in the treatment of unruptured abdominal aortic aneurysms: meta-analysis and systematic review. Cureus2020; 12: e9683. DOI: 10.7759/CUREUS.9683.
4.
DoganerOJongkindVBlankensteijnJD, et al.A standardized bolus of 5 000 IU of heparin does not lead to adequate heparinization during non-cardiac arterial procedures. Ann Vasc Surg2020; 0: 1–7. DOI: 10.1016/j.avsg.2020.07.035.
5.
MurrayG. Heparin in surgical treatment of blood vessels. Arch Surg1940; 40: 307. DOI: 10.1001/archsurg.1940.04240010147010.
6.
de SwartCNijmeyerBRoelofsJ, et al.Kinetics of intravenously administered heparin in normal humans. Blood1982; 60: 1251–1258. DOI: 10.1182/BLOOD.V60.6.1251.1251.
7.
OlssonPLagergrenHEkS. The elimination from plasma of intravenous heparin an experimental study on dogs and humans. Acta Med Scand1963; 173: 619–630. DOI: 10.1111/J.0954-6820.1963.TB17446.X.
8.
DoganerOWiersemaAMScholtesV, et al.No concluding evidence on optimal activated clotting time for non-cardiac arterial procedures. Eur J Vasc Endovasc Surg2020; 59: 137–147. DOI: 10.1016/j.ejvs.2019.08.007.
9.
PageMJMcKenzieJEBossuytPM, et al.The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ2021; 372: n71. DOI: 10.1136/BMJ.N71.
10.
Treat-JacobsonDJRichKDeVeauxT, et al.Society for Vascular Nursing clinical practice guideline (CPG) for carotid artery stenting. J Vasc Nurs2013; 31: 32–55. DOI: 10.1016/J.JVN.2012.12.003.
11.
RichKTreat-JacobsonDDeVeauxT, et al.Society for Vascular Nursing-Carotid endarterectomy (CEA) updated nursing clinical practice guideline. J Vasc Nurs2017; 35: 90–111. DOI: 10.1016/J.JVN.2017.03.004.
12.
ChangHWShinSHSuhS, et al.Recommendations for carotid stenting in korea. Neurointervention2015; 10: 7–13. DOI: 10.5469/NEUROINT.2015.10.1.7.
13.
BatesERBabbJDCaseyDE, et al.ACCF/SCAI/SVMB/SIR/ASITN 2007 clinical expert consensus document on carotid stenting. Vasc Med2007; 12: 35–83. DOI: 10.1177/1358863X06076103.
14.
HigashidaRTMeyersPMPhatourosCC, et al.Reporting standards for carotid artery angioplasty and stent placement. J Vasc Intervent Radiol2004; 15: 421–422. DOI: 10.1097/01.RVI.0000128204.73150.C8.
15.
NaylorRRantnerBAncettiS, et al.Editor’s choice – European society for vascular surgery (ESVS) 2023 clinical practice guidelines on the management of atherosclerotic carotid and vertebral artery disease. Eur J Vasc Endovasc Surg2023; 65: 7–111. DOI: 10.1016/J.EJVS.2022.04.011.
16.
SawJBajzerCCasserlyIP, et al.Evaluating the optimal activated clotting time during carotid artery stenting. Am J Cardiol2006; 97: 1657–1660. DOI: 10.1016/j.amjcard.2005.12.062.
17.
KakisisJDAntonopoulosCNMoulakakisKG, et al.Protamine reduces bleeding complications without increasing the risk of stroke after carotid endarterectomy: a meta-analysis. Eur J Vasc Endovasc Surg2016; 52: 296–307. DOI: 10.1016/J.EJVS.2016.05.033.
18.
StoneDHNolanBWSchanzerA, et al.Protamine reduces bleeding complications associated with carotid endarterectomy without increasing the risk of stroke. J Vasc Surg2010; 51: 559–564.e1. DOI: 10.1016/J.JVS.2009.10.078.
19.
PatelRBBeaulieuPHomaK, et al.Shared quality data are associated with increased protamine use and reduced bleeding complications after carotid endarterectomy in the Vascular Study Group of New England. J Vasc Surg2013; 58: 1518–1524.e1. DOI: 10.1016/J.JVS.2013.06.064.
20.
DellagrammaticasDLewisSCGoughMJ, et al.Is heparin reversal with protamine after carotid endarterectomy dangerous?Eur J Vasc Endovasc Surg2008; 36: 41–44. DOI: 10.1016/J.EJVS.2008.01.021.
21.
UberoiRTsetisDShrivastavaV, et al.Standard of practice for the interventional management of isolated iliac artery aneurysms. Cardiovasc Intervent Radiol2011; 34: 3–13. DOI: 10.1007/S00270-010-0055-0.
22.
ChaikofELDalmanRLEskandariMK, et al.The Society for Vascular Surgery practice guidelines on the care of patients with an abdominal aortic aneurysm. J Vasc Surg2018; 67: 2–77. DOI: 10.1016/j.jvs.2017.10.044.
23.
WanhainenAVerziniFVan HerzeeleI, et al.Editor's choice - European society for vascular surgery (ESVS) 2019 clinical practice guidelines on the management of abdominal aorto-iliac artery aneurysms. Eur J Vasc Endovasc Surg2019; 57: 8–93. DOI: 10.1016/j.ejvs.2018.09.020.
24.
BuckleyCJBuckleySD. Technical tips for endovascular repair of common iliac artery aneurysms. Semin Vasc Surg2008; 21: 31–34. DOI: 10.1053/J.SEMVASCSURG.2008.01.001.
25.
WalkerTGKalvaSPYeddulaK, et al.Clinical practice guidelines for endovascular abdominal aortic aneurysm repair: written by the standards of practice committee for the society of interventional radiology and endorsed by the cardiovascular and interventional radiological society of Europe and the Canadian interventional radiology association. J Vasc Intervent Radiol2010; 21: 1632–1655. DOI: 10.1016/J.JVIR.2010.07.008.
26.
ErbelRAboyansVBoileauC, et al.2014 ESC Guidelines on the diagnosis and treatment of aortic diseases: document covering acute and chronic aortic diseases of the thoracic and abdominal aorta of the adult. The Task Force for the Diagnosis and Treatment of Aortic Diseases of the European Society of Cardiology (ESC). Eur Heart J2014; 35: 2873–2926. DOI: 10.1093/EURHEARTJ/EHU281.
27.
Kohlman-TrigoboffDRichKFoleyA, et al.Society for Vascular Nursing endovascular repair of abdominal aortic aneurysm updated nursing clinical practice guideline. J Vasc Nurs2020; 38: 36–65. DOI: 10.1016/J.JVN.2020.01.004.
28.
PratesiCEspositoDApostolouD, et al.Guidelines on the management of abdominal aortic aneurysms: updates from the Italian Society of Vascular and Endovascular Surgery (SICVE). J Cardiovasc Surg2022; 63: 328–352.
29.
ThompsonJFMulleeMABellPRF, et al.Intraoperative heparinisation, blood loss and myocardial infarction during aortic aneurysm surgery: a Joint Vascular Research Group study. Eur J Vasc Endovasc Surg1996; 12: 86–90. DOI: 10.1016/S1078-5884(96)80281-4.
30.
WiersemaAMJongkindVBruijninckxCMA, et al.Prophylactic perioperative anti-thrombotics in open and endovascular abdominal aortic aneurysm (AAA) surgery: a systematic review. Eur J Vasc Endovasc Surg2012; 44: 359–367. DOI: 10.1016/j.ejvs.2012.06.008.
31.
ClagettGPSobelMJacksonMR, et al.Antithrombotic therapy in peripheral arterial occlusive disease: the seventh ACCP conference on antithrombotic and thrombolytic therapy. Chest2004; 126: 609S–626. DOI: 10.1378/CHEST.126.3_SUPPL.609S.
32.
KatsanosKTepeGTsetisD, et al.Standards of practice for superficial femoral and popliteal artery angioplasty and stenting. Cardiovasc Intervent Radiol2014; 37: 592–603. DOI: 10.1007/S00270-014-0876-3.
33.
KimYHBaeJIJeonYS, et al.Korean guidelines for interventional recanalization of lower extremity arteries. Korean J Radiol2015; 16: 696–722. DOI: 10.3348/KJR.2015.16.4.696.
34.
StonerMCCalligaroKDChaerRA, et al.Reporting standards of the Society for Vascular Surgery for endovascular treatment of chronic lower extremity peripheral artery disease. J Vasc Surg2016; 64: 21–e21. DOI: 10.1016/J.JVS.2016.03.420.
35.
TsetisDBelliAM. Guidelines for stenting in infrainguinal arterial disease. Cardiovasc Intervent Radiol2004; 27: 198–203. DOI: 10.1007/S00270-004-0029-1.
RossiMIezziR. Cardiovascular and Interventional Radiological Society of Europe guidelines on endovascular treatment in aortoiliac arterial disease. Cardiovasc Intervent Radiol2014; 37: 13–25. DOI: 10.1007/S00270-013-0741-9.
38.
AlimiYHauguelACasbasL, et al.French guidelines for the management of ambulatory endovascular procedures for lower extremity peripheral artery disease. Ann Vasc Surg2019; 59: 248–258. DOI: 10.1016/J.AVSG.2019.05.001.
39.
AndreozziGMKalodikiEGašparLL, et al.Consensus document on intermittent claudication from the central European vascular Forum (C.E.V.F.)-3rd revision (2013) with the sharing of the mediterranean league of Angiology and vascular surgery, and the north africa and Middle East chapter of international union of Angiology. Int Angiol. 2014; 33(4): 329–47, PMID: 25056165.
40.
KleinAJPintoDSGrayBH, et al.SCAI expert consensus statement for femoral-popliteal arterial intervention appropriate use. Cathet Cardiovasc Interv2014; 84: 529–538. DOI: 10.1002/CCD.25504.
41.
TroisiNBaccellieriDBiscettiF, et al.International Union of Angiology Position Statement on perioperative drug and hemostasis management in vascular surgery. Int Angiol2022; 41: 420–432.
42.
BaglinTBarrowcliffeTWCohenA, et al.Guidelines on the use and monitoring of heparin. Br J Haematol2006; 133: 19–34. DOI: 10.1111/J.1365-2141.2005.05953.X.
43.
DormanBHElliottBMSpinaleFG, et al.Protamine use during peripheral vascular surgery: a prospective randomized trial. J Vasc Surg1995; 22(3): 248–255. DOI: 10.1016/S0741-5214(95)70137-0.
44.
FearnSJParryADPictonAJ, et al.Should heparin be reversed after carotid endarterectomy? A randomised prospective trial. Eur J Vasc Endovasc Surg1997; 13: 394–397. DOI: 10.1016/S1078-5884(97)80082-2.
45.
KasapisCGurmHSChetcutiSJ, et al.Defining the optimal degree of heparin anticoagulation for peripheral vascular interventions insight from a large, regional, multicenter registry. Circ Cardiovasc Interv2010; 3: 593–601. DOI: 10.1161/CIRCINTERVENTIONS.110.957381.
46.
CzernyMSchmidliJAdlerS, et al.Current options and recommendations for the treatment of thoracic aortic pathologies involving the aortic arch: an expert consensus document of the European Association for Cardio-Thoracic surgery (EACTS) and the European Society for Vascular Surgery (ESVS). Eur J Cardio Thorac Surg2019; 55: 133–162. DOI: 10.1093/EJCTS/EZY313.
47.
SvenssonLGKouchoukosNTMillerDC, et al.Expert consensus document on the treatment of descending thoracic aortic disease using endovascular stent-grafts. Ann Thorac Surg2008; 85: S1–S41. DOI: 10.1016/J.ATHORACSUR.2007.10.099.
48.
RoosendaalLCWiersemaAMSmitJW, et al.Editor's choice - sex differences in response to administration of heparin during non-cardiac arterial procedures. Eur J Vasc Endovasc Surg2022; 64: 557–565. DOI: 10.1016/J.EJVS.2022.08.005.
AvendanoAFergusonJJ. Comparison of Hemochron and HemoTec activated coagulation time target values during percutaneous transluminal coronary angioplasty. J Am Coll Cardiol1994; 23: 907–910. DOI: 10.1016/0735-1097(94)90636-X.
51.
DohertyTMShavelleRMFrenchWJ. Reproducibility and variability of activated clotting time measurements in the cardiac catheterization laboratory. Cathet Cardiovasc Interv2005; 65: 330–337. DOI: 10.1002/CCD.20355.
52.
ChiaSVan CottEMRaffelOC, et al.Comparison of activated clotting times obtained using Hemochron and Medtronic analysers in patients receiving anti-thrombin therapy during cardiac catheterisation. Thromb Haemostasis2009; 101: 535–540. DOI: 10.1160/TH08-08-0528.
53.
LeeJMParkEYKimKM, et al.Comparison of activated clotting times measured using the Hemochron Jr. Signature and Medtronic ACT Plus during cardiopulmonary bypass with acute normovolemic haemodilution. J Int Med Res2018; 46: 873–882. DOI: 10.1177/0300060517731952.
54.
ThenappanTSwamyRShahA, et al.Interchangeability of activated clotting time values across different point-of-care systems. Am J Cardiol2012; 109: 1379–1382. DOI: 10.1016/J.AMJCARD.2011.12.033.
55.
BrottTGHalperinJLAbbaraS, et al.2011 ASA/ACCF/AHA/AANN/AANS/ACR/ASNR/CNS/SAIP/SCAI/SIR/SNIS/SVM/SVS guideline on the management of patients with extracranial carotid and vertebral artery disease: executive summary. A report of the American College of Cardiology foundation/American heart association task force on practice guidelines, and the American stroke association, American association of neuroscience nurses, American association of neurological surgeons, American College of radiology, American society of Neuroradiology, congress of neurological surgeons, society of atherosclerosis imaging and prevention, society for cardiovascular Angiography and interventions, society of interventional radiology, society of NeuroInterventional surgery, society for vascular medicine, and society for vascular surgery. Circulation2011; 124: 489–532. DOI: 10.1161/CIR.0B013E31820D8D78.
56.
GortlerDSchlösserFJVMuhsBE, et al.Periprocedural drug therapy in carotid artery stenting: the need for more evidence. Vascular2008; 16: 303–309. DOI: 10.2310/6670.2008.00081.
57.
TremeyBSzekelyBSchlumbergerS, et al.Anticoagulation monitoring during vascular surgery: accuracy of the Hemochron low range activated clotting time (ACT-LR). Br J Anaesth2006; 97: 453–459. DOI: 10.1093/BJA/AEL194.
58.
GoldhammerJEZimmermanD. Pro: activated clotting time should Be monitored during heparinization for vascular surgery. J Cardiothorac Vasc Anesth2018; 32: 1494–1496. DOI: 10.1053/j.jvca.2017.04.047.
59.
AltenburgAHaageP. Antiplatelet and anticoagulant drugs in interventional radiology. Cardiovasc Intervent Radiol2012; 35: 30–42. DOI: 10.1007/S00270-011-0204-0.
60.
HirschATHaskalZJHertzerNR, et al.ACC/AHA 2005 practice guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): a collaborative report from the American association for vascular surgery/society for vascular surgery, society for cardiovascular Angiography and interventions, society for vascular medicine and biology, society of interventional radiology, and the ACC/AHA task force on practice guidelines (writing committee to develop guidelines for the management of patients with peripheral arterial disease): endorsed by the American association of cardiovascular and pulmonary rehabilitation; national heart, lung, and blood institute; society for vascular nursing; TransAtlantic inter-society consensus; and vascular disease foundation. Circulation2006; 113: 463–654. DOI: 10.1161/CIRCULATIONAHA.106.174526.
61.
PaganoDMilojevicMMeestersMI, et al.2017 EACTS/EACTA Guidelines on patient blood management for adult cardiac surgery. Eur J Cardio Thorac Surg2018; 53: 79–111. DOI: 10.1093/EJCTS/EZX325.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
